RecruitingEarly Phase 1NCT05011760

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2)

Sponsor

Rajesh Narendran

Enrollment

30 participants

Start Date

Jan 31, 2021

Study Type

INTERVENTIONAL

Conditions

Cocaine Use Disorder

Summary

This study uses \[11C\]NPA positron emission tomography (PET) and a d-amphetamine challenge to image amphetamine induced dopamine release in the striatum in subjects with cocaine use disorders (CUD). Amphetamine-induced dopamine release data from this study will be correlated with \[11C\]NOP-1A VT measured at baseline in the midbrain. \[11C\]NOP-1A PET data will be used from aim 1 (see, Study Record: Imaging CRF X NOP interactions in Cocaine Use Disorders)

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Baseline [C-11]NPA PET Scan, Post-amphetamine [C-11]NPA PET Scan, and others for people with cocaine use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONBaseline [C-11]NPA PET Scan

Radiotracer

DRUGd-amphetamine

Oral, 0.5 mg/Kg

RADIATIONPost-amphetamine [C-11]NPA PET Scan

Radiotracer

Locations(1)

University of PIttsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05011760

Related Trials

Open-label Feasibility Trial of HD-tDCS During Cognitive Behavioral Therapy for Cocaine Use Disorder

NCT07829263

Imaging Mitochondrial Complex-I in Cocaine Use Disorder: a [F-18]BCPP-EF PET Study

NCT07773649